Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 3/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GPR174 | Q9BXC1 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL390496 | 0.84 | MAPT (0.53) | MAPTL3MBTL1HTTKMT2AALDH1A1 | |
| SCHEMBL4707378 | 0.83 | MAPT (0.40) | SMN1; SMN2MAPTL3MBTL1HTTKMT2A | |
| SCHEMBL1673930 | 0.77 | GPR119 (0.51) | SMN1; SMN2 | |
| SCHEMBL5048668 | 0.76 | SMN1; SMN2 (0.41) | SMN1; SMN2MAPTL3MBTL1HTTTHRB | |
| SCHEMBL389075 | 0.76 | SMN1; SMN2 (0.40) | SMN1; SMN2MAPTL3MBTL1THRBALDH1A1 | |
| SCHEMBL388928 | 0.76 | THRB (0.44) | SMN1; SMN2MAPTL3MBTL1HTTTHRB | |
| SCHEMBL5577991 | 0.74 | MAPT (0.40) | SMN1; SMN2MAPTL3MBTL1HTTTHRB | |
| SCHEMBL389375 | 0.74 | THRB (0.43) | SMN1; SMN2MAPTL3MBTL1HTTTHRB | |
| SCHEMBL386162 | 0.73 | MAPT (0.40) | SMN1; SMN2MAPTL3MBTL1HTTTHRB | |
| SCHEMBL388752 | 0.73 | THRB (0.43) | SMN1; SMN2MAPTL3MBTL1HTTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1606282-B1 | PHENYL- AND PYRIDYLPIPEREIDINYE-DERIVATIVES AS MODULATORS OF GLUCOSE METABOLISM | ARENA PHARM INC (US) | 2008-11-12 | — | — | EP | claimed |
| US-20070066590-A1 | Phenyl-and pyridylpiperidine-derivatives as modulators of glucose metabolism | ARENA PHARMACEUTICALS, INC. | 2007-03-22 | — | — | US | claimed |
| EP-1606282-A2 | PHENYL- AND PYRIDYLPIPEREIDINYE-DERIVATIVES AS MODULATORS OF GLUCOSE METABOLISM | Arena Pharmaceuticals, Inc. (US) | 2005-12-21 | — | — | EP | claimed |
| WO-2004076413-A2 | PHENYL- AND PYRIDYLPIPERIDINE-DERIVATIVES AS MODULATORS OF GLUCOSE METABOLISM | ARENA PHARMACEUTICALS, INC. (US) | 2004-09-10 | — | — | WO | claimed |
| EP-1758565-B2 | Method of identifying GLP-1 secretagogues | ARENA PHARM INC (US) | 2012-11-14 | — | — | EP | disclosed |
| US-8198232-B2 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8101626-B2 | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | ARENA PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8030270-B2 | Methods for identifying GLP-1 secretagogues | ARENA PHARMACEUTICALS, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8022034-B2 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-8003597-B2 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| EP-2322156-A1 | Composition for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | Arena Pharmaceuticals, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| EP-2322151-A2 | Sustained release formulation comprising a GPR119 agonist and a DPP-IV inhibitor | Arena Pharmaceuticals, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| US-20070066590-A1 | Phenyl-and pyridylpiperidine-derivatives as modulators of glucose metabolism | ARENA PHARMACEUTICALS, INC. | 2007-03-22 | — | — | US | disclosed |
| US-20070066590-A1 | Phenyl-and pyridylpiperidine-derivatives as modulators of glucose metabolism | ARENA PHARMACEUTICALS, INC. | 2007-03-22 | — | — | US | disclosed |
| US-20070066590-A1 | Phenyl-and pyridylpiperidine-derivatives as modulators of glucose metabolism | ARENA PHARMACEUTICALS, INC. | 2007-03-22 | — | — | US | disclosed |
| EP-1758565-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | Arena Pharmaceuticals, Inc. (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006076231-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | ARENA PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060154866-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS, INC. | 2006-07-13 | — | — | US | disclosed |
| EP-1606282-A2 | PHENYL- AND PYRIDYLPIPEREIDINYE-DERIVATIVES AS MODULATORS OF GLUCOSE METABOLISM | Arena Pharmaceuticals, Inc. (US) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004076413-A2 | PHENYL- AND PYRIDYLPIPERIDINE-DERIVATIVES AS MODULATORS OF GLUCOSE METABOLISM | ARENA PHARMACEUTICALS, INC. (US) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066590-A1 | Phenyl-and pyridylpiperidine-derivatives as modulators of glucose metabolism | GPR119, PC, PLPBP | SMN1; SMN2 4612/4885MAPT 3871/4885L3MBTL1 4254/4885 |
| US-20060154866-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | GLP1R, GPR119, GIPR | SMN1; SMN2 3911/4885MAPT 4045/4885L3MBTL1 3351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.